PRELP 被认为是多种恶性肿瘤发生和进展的抑制剂。转移是结直肠癌患者死亡的主要原因，但 PRELP 在结直肠癌转移中的作用机制仍知之甚少。本研究发现结直肠癌转移组织中 PRELP 显着高于非转移组织，且与结直肠癌患者不良预后密切相关。 PRELP 促进结直肠癌细胞的生长和转移。 PRELP 可降低细胞硬度和粘附力。 PRELP促进结直肠癌细胞的EMT，并且PRELP与整合素α5结合激活整合素α5/FAK/AKT信号通路。总之，我们证明 PRELP 在转移性结直肠癌中表达上调，从生物力学角度为转移性结直肠癌的临床管理提供了潜在的预后标志物和治疗靶点。版权所有 © 2024。由 Elsevier Inc. 出版。

PRELP is thought to be an inhibitor of the development and progression of a variety of malignancies. Metastasis is a major cause of death in patients with colorectal cancer, but the mechanism underlying the role of PRELP in colorectal cancer metastasis remains poorly understood. In this study, we found that PRELP was significantly higher in metastatic tissues than in non-metastatic tissues of colorectal cancer and was closely associated with poor prognosis of colorectal cancer patients. PRELP promotes growth and metastasis of colorectal cancer cells. PRELP reduces cell stiffness and adhesion. PRELP promoted EMT in colorectal cancer cells and that PRELP bind to integrin α5 to activate the integrin α5/FAK/AKT signaling pathway. In conclusion, we demonstrate that PRELP is upregulated in metastatic colorectal cancer, providing a potential prognostic marker and therapeutic target for the clinical management of metastatic colorectal cancer from a biomechanical perspective.Copyright © 2024. Published by Elsevier Inc.